

1 Clinical validation of an RSV neutralization assay and testing of cross-sectional sera pre- and post- RSV outbreaks
2 from 2021-2023

3

4 Eli A. Piliper¹, Jonathan Reed¹, Alexander L. Greninger^{1,2, #}

5

6

7 ¹ Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, WA, USA

8 ² Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

9

10 # Corresponding author:

11 Alexander L. Greninger

12 Department of Laboratory Medicine and Pathology, University of Washington Medical Center

13 850 Republican St, Seattle, WA 98109, USA

14 Email: agrening@uw.edu

15

16

17 **Highlights**

18

19

- We report the full clinical validation of an RSV neutralization assay

20

- No evidence of immune debt found in Washington State RSV 2022-2023 outbreak

21

- Our assay offers high throughput testing applicable to vaccine/drug studies

22

23 **Abstract**

24 **Background:** Respiratory syncytial virus (RSV) is a leading cause of acute respiratory infections and hospitalization
25 in infants and the elderly. Newly approved vaccines and the prophylactic antibody nirsevimab have heightened
26 interest in RSV immunologic surveillance, necessitating development of high-throughput assays assessing anti-RSV
27 neutralizing activity.

28 **Objectives:** We validated an RSV focus-reduction neutralization test (RSV FRNT), a high-throughput, automation-
29 ready neutralization assay using RSV strain A2. The assay was then used to investigate the immunity debt
30 hypothesis for resurgent RSV outbreaks in the 2022-2023 season.

31 **Study design:** We evaluated precision, sensitivity, specificity, linearity, and accuracy of RSV FRNT using reference
32 sera, contrived specimens, and clinical remnant specimens. RSV neutralizing activity of remnant serum specimens,
33 sampled for HSV-1/2 antibody testing during and after the COVID-19 pandemic (February and September 2022 &
34 2023), was measured and correlated with concurrent trends in RSV prevalence.

35 **Results:** RSV FRNT was shown to be accurate, generating reference serum neutralizing titers within 2-fold of
36 established assays, with a linear analytical measurement range between 20 to 4,860 ND50 and ND80 units.
37 Neutralizing activity measured with the assay was positively correlated with antibody titer determined via indirect
38 ELISA ($\rho = 1.0$, $p = 0.0014$). Among individuals sampled within 3 months of RSV PCR test, RSV positives had a 9.14-
39 fold higher geometric mean neutralizing titer (GMT) relative to RSV PCR negatives ($p = 0.09$). There was no
40 difference in geometric mean anti-RSV neutralizing titers between sera sampled pre- and post-2023 RSV outbreak
41 ($p = 0.93$).

42 **Conclusions:** We validated a high-throughput assay for assessing anti-RSV neutralizing activity and found no
43 significant difference in neutralizing titers between pre- and post-pandemic outbreak specimens.

44

45

46 Introduction

47 RSV is one of the most common causes of lower respiratory tract infections worldwide, infecting
48 approximately 64 million people and causing at least 160,000 deaths and 3 million hospitalizations each year [1,2].
49 2023 has seen multiple revolutions in RSV disease prevention, including the FDA approval of two vaccines for older
50 adults and pregnant individuals as well as the prophylactic monoclonal antibody (mAb) nirsevimab for prevention
51 of RSV lower respiratory tract disease in neonates and infants [3,4]. In addition, the past two years have seen global
52 resurgence of aseasonal RSV infections thought to be related to limited circulation and immunity debt attributed to
53 the COVID-19 pandemic [3,5–8]. These developments necessitate monitoring population immunity and vaccine
54 immunogenicity, both best assessed by measuring neutralizing antibodies against RSV [9–12]. RSV neutralizing
55 antibody titer is a major correlate of protection, with higher neutralizing titers being associated with lower viral
56 load and reduced risk of severe RSV-induced disease [13–18].

57 The standard for neutralization assays, the plaque-reduction neutralization test (PRNT), requires 3-5 days
58 of incubation time and is less amenable to high-throughput applications [12]. An alternative is the focus-reduction
59 neutralization test (FRNT), which often requires less sample, reagent volume, and incubation time (26-30 hours) to
60 measure neutralizing titers. A RSV FRNT assay can be performed in a 96-well plate format portable to liquid
61 handlers for higher throughput and less inter- and intra-assay variability [19–22]. Strain-specific reporter viruses
62 are utilized by some FRNTs to visualize foci but require development of a recombinant virus, potentially delaying
63 efforts to implement contemporary strains in testing. A FRNT using chromogen-conjugated secondary antibodies to
64 visualize foci is easy to implement, allowing scalability for high-throughput applications such as vaccine evaluation,
65 population immunity monitoring, and testing for vaccine- and nirsevimab-resistant strains [23].

66 Here, we describe the validation of a RSV FRNT, an automation-ready, high-throughput, standardized
67 method for assessing serum neutralizing activity against RSV in clinical and research settings. In addition, we use
68 the RSV FRNT to monitor population immunity against RSV in remnant serum specimens taken before, during, and
69 after the 2022-2023 RSV outbreak.

70

71 Materials and Methods

72 Virus and cell line

73 Assays were run with RSV A2 as the challenge virus (ATCC, VR-1516), unless otherwise specified. RSV B strain
74 WV/14617/85 (ATCC, VR-1400) challenge experiments are described in Supplemental Methods. VeroE6 cells were
75 seeded in DMEM-10 in transparent 96-well plates (Corning, 3585) at 10,000 cells/well and grown for 24 hours prior
76 to infection.

77 **Clinical specimens**

78 Plasma or sera from patients with a history of positive RT-PCR test for RSV or influenza virus since October 1, 2023
79 were obtained from University of Washington (UW) Medicine patients that were sampled during peak RSV
80 incidence (mid-November 2023 to January 2024) and no later than 40 days following PCR testing. Remnant
81 serology specimens sent for rubella IgG testing were obtained from UW Virology. Cross-sectional sera were
82 obtained from remnant specimens sent for HSV-1/2 Western Blot testing in February 2022, July 2022, February
83 2023, and July 2023 (n=47 for each timepoint). This study was approved by the UW Medicine Institutional Review
84 Board with consent waiver (STUDY00010205). Individual line-item data and metadata is provided in Table S1. For
85 individuals with recorded RSV PCR tests, time delta (in days) between serum collection and RSV PCR test date is
86 shown in Figure S1.

87 **Measurement of RSV neutralizing activity**

88 **Microneutralization** All sera were heat inactivated (HI) at 56 ° C for 30 minutes prior to testing. HI serum was
89 diluted initially 10-fold by combining 10.5 µL HI serum with 94.5 µL DMEM-10. This was followed by five 3-fold
90 dilutions by serially transferring 35 µL of diluted serum into 70 µL of DMEM-10, resulting in a final dilution series
91 from 10-fold to 2430-fold and a final volume of 70 µL for each dilution. These serial dilutions of serum were diluted
92 an additional two-fold to a final volume of 140 µL with 70 µL of RSV A2, diluted to form a final of 120-250 ffu/well
93 in the assay, resulting in a final dilution series of 20-fold to 4,860-fold. Serum-virus mixtures were incubated at 37°
94 C 5% CO₂ for 1 h. 96-well plates seeded with 10,000 VeroE6 cells/well were infected with 50 µL/well of serum-virus
95 mixture in duplicate. Plates were incubated at 37° C 5% CO₂ for 26 – 30 hours before fixation. Exogenous
96 complement, typically[13,24] used to boost neutralizing signal from low-titer sera, was not used in our RSV FRNT;
97 instead, samples with neutralizing titers below the lower limit of quantitation were retested at a lower, 5-fold initial
98 dilution to obtain reportable ND50 and ND80 values within assay analytical measurement range (20-4,860).

99 **Focus-forming assay** Assay plates were fixed for 60 minutes at room temperature (approximately 21-25 ° C) with 25
100 μL (1/2 well volume) of 4% formaldehyde prepared in DPBS with 100 mg/L calcium and 100 mg/L magnesium.
101 After fixation, plates were washed three times with 150 μL room-temperature 1xPBS and incubated for 2 h at room
102 temperature with 50 μL /well of mouse mAb 131-2G against RSV-A2 F-protein (Sigma-Aldrich, MAB8582) diluted
103 4000-fold in FFA staining buffer (composed of 1x PBS, 1 mg/mL saponin, and 0.1% IgG-free BSA). Plates were then
104 washed three times with 150 μL room-temperature FFA wash buffer (composed of 1x PBS and 0.05% Triton X-100).
105 Plates were incubated for 1 h at room temperature with 50 μL /well of peroxidase-conjugated secondary antibody
106 (Bethyl Laboratories, A90216P) diluted 4000-fold in FFA staining buffer. Following secondary incubation plates were
107 then washed three times with 150 μL room-temperature FFA wash buffer. Plates were developed with 50 μL
108 TrueBlue peroxidase substrate (KPL, 5510-0054) for 15 minutes at room temperature. Development was stopped
109 by washing three times with 150 μL room-temperature deionized water, and the plates were dried for 10-15
110 minutes to minimize visual artifacts from liquid.

111 **Imaging and counting** Plates were scanned and counted on the S6 Universal M2 ImmunoSpot analyzer (Cellular
112 Technology Ltd, Cleveland, OH). See supplementary information for counting settings. Counts were used to
113 determine percent foci reduction at each dilution. For each specimen, the response between percent foci reduction
114 and serum dilution was modeled via 4-parameter logistic regression (Supplementary Material), which was used to
115 obtain ND50 and ND80 values.

116

117 **Results**

118 *Assay Accuracy*

119 To determine if RSV FRNT results closely reflected binding antibody titers, we tested remnant rubella
120 serology specimens and contrived serum samples via RSV FRNT and anti-RSV IgG indirect ELISA testing
121 (Supplementary Methods), with the expectation that specimens with higher ND50 values would have higher anti-
122 RSV antibody titers by ELISA [25]. We prepared a “linearity panel” of six contrived specimens derived from NR-
123 21973 reference serum with theoretical ND50 values ranging from 15-14,982 (Supplemental Methods). We tested
124 these alongside 22 remnant rubella serology specimens. RSV FRNT ND50 values of linearity panel members were
125 positively correlated ($\rho = 1$, $p = 0.0014$) with the level of RSV-reactive antibodies detected by ELISA (Figure 1A). All

126 22 rubella serology specimens tested positive for neutralizing antibodies by FRNT, with ND50 values spanning the
127 full range of measurable ND50 values between the lowest to highest serum dilutions (20-4,860). Similarly, 21 of 22
128 rubella serology specimens were positive for RSV-reactive antibodies by ELISA based on the manufacturer's cutoff.
129 The one remnant rubella serology specimen that fell just below the ELISA positive cutoff had an ND50 of 864. An Ig-
130 depleted control exhibited an ND50 < 20 in the RSV FRNT assay and fell below the ELISA positive cutoff (Figure 1A).

131 We next compared ND50 values of our RSV FRNT assay with an independent reference assay on
132 commercially available sera and standardized results of the First International Standard for Antiserum to Respiratory
133 Syncytial Virus (NIBSC code: 16/284) [26]. RSV FRNT results were within 2-fold of previously published values (Table
134 1) [26]. FRNT results were also within 2-fold of proposed reference measurements when using RSV strain B
135 WV/14617/85 (Table 2) 6/13/2024 10:32:00 AM. The conversion factor for RSV A2 and RSV B FRNT ND50 units to
136 IU/mL was 0.37 and 0.91, respectively.

137

138 *Assay Linearity, Precision, Reportable Range, and Limits of Quantitation*

139 We next analyzed ND50 and ND80 results from the linearity panel by linear regression. Linearity panel
140 ND50 and ND80 results within or near the assay lowest and highest dilutions (20-4,860) were strongly linear ($R^2 >$
141 0.9), with slopes of 1.00 and 1.05, respectively. This met our assay acceptance criteria of $R^2 > 0.9$ and slope
142 between 0.9 and 1.1 (Figure 1B, Table S2).

143 We established our maximum acceptable geometric coefficient of variation (GCV) to be 37%, based on
144 CLSI and FDA requirements [28], and precision criteria of similar assays [29–39] (see Supplemental Material for
145 further discussion). To estimate intra-assay, inter-assay, and overall imprecision, we ran four linearity panel
146 specimens (in duplicate over 3 days, Figure 1C) and five rubella serology specimens (in duplicate over 2 days, Figure
147 1D). No specimen, clinical or contrived, exhibited intra-assay, inter-assay, or overall GCV above 37% (Table S3 and
148 S4). Measurements on reference serum using RSV B WV/14617/85 as a challenge virus also had GCV < 37% (Table
149 S5).

150 Per the precision analysis, ND50 and ND80 GCV was < 37% near the minimum and maximum dilutions (20
151 and 4,860), and assay measurements were linear through this range. Thus, the lower limit of quantitation and
152 upper limit of quantitation of the assay were determined to be 20 and 4,860, respectively, for both ND50 and

153 ND80. To verify values above the analytical measurement range, we prepared four dilutions of NR-21973 (ND50
154 29,963) and recovered values within 1.2-fold of original ND50 values (Supplementary Material, Table S6).

155

156 *Comparison of 2021-2023 RSV neutralization titers associated with RSV outbreaks*

157 To investigate the role of population-level immune debt in the winter 2022 RSV outbreak, we determined
158 the geometric mean titer (GMT, geometric mean of ND50 measurements) of a repeated cross-sectional collection
159 of 193 remnant sera sent for clinical HSV western blot testing sampled across four discrete timepoints between
160 2022-2023: after 2021 RSV outbreak (February 2022), before (August 2022) and after (February 2022) 2022 RSV-
161 outbreak, and before 2023 RSV outbreak (September 2023, Figure 2). We found no significant difference in GMT or
162 median geometric titer between any combination of the four timepoints (one-way ANOVA, $p = 0.86$). Moreover,
163 samples collected before and after the 2022 RSV outbreak exhibited no significant difference in GMT (Wilcoxon
164 ranked-sum test, $p = 0.68$, Figure 2). In addition to the cross-sectional remnant HSV sera, we tested RSV
165 neutralizing titers of a separate group of remnant HSV serology serum specimens from 26 individuals who tested
166 PCR positive for RSV after serum collection (by 25 – 463 days), referred to as future-RSV-PCR-positives. The overall
167 GMT from these individuals was not significantly different from the cross-sectional sera for which RSV PCR testing
168 data was not available (two-sided t-test, $p = 0.24$, Figure 3).

169 To further profile neutralizing titers in individuals testing PCR positive or negative for RSV, we collected
170 remnant sera from UW Medicine patients who had recently (within 3 months of sampling) tested PCR positive for
171 RSV ($n=29$) or PCR negative for RSV and positive for influenza virus ($n=10$) during the 2023-2024 respiratory season
172 (Figure 3). The PCR positive RSV group included 9 immunosuppressed individuals based on chart review and were
173 separated into their own group for this analysis. Population GMT (combined cross-sectional HSV serology remnant
174 specimens sets described above) was 4.2-fold lower than immunocompetent RSV PCR positive individuals (two-
175 sided t-test, $p = 0.51$), 4.1-fold higher than that of RSV PCR positive immunosuppressed individuals ($p = 0.008$), and
176 2.14-fold higher than that of influenza PCR-positive, RSV PCR-negative individuals ($p = 0.04$). The future-RSV-PCR-
177 positive samples had a GMT 4.7-fold higher than PCR positive, immunosuppressed individuals ($p = 0.03$) and 3.5-
178 fold lower than PCR positive individuals without immunosuppression ($p = 0.24$). Immunocompetent RSV PCR
179 positive individuals had a GMT 17.4-fold higher than that of RSV PCR positive immunosuppressed individuals ($p =$

180 0.007), and 9.14-fold higher than Influenza PCR-positive, RSV PCR-negative individuals ($p=0.09$). Thus, the
181 measurements obtained by RSV FRNT align with patient medical background and can represent individuals ranging
182 from the recently infected and immunocompetent to the immunosuppressed.

183

184 Discussion

185 Here, we designed and validated a high-throughput RSV neutralization assay amenable to clinical testing,
186 clinical trials, and seroprevalence studies. As a precise, sensitive, and linear assay standardizable to the NIBSC
187 16/284 RSV neutralizing reference material, RSV FRNT is an alternative to reporter virus methods, allowing for
188 similar throughput, quantification, and precision unlimited by development of recombinant viruses. The potential
189 to use wild-type strains as challenge viruses also enables monitoring for nirsevimab resistance and vaccine evasion
190 by RSV, which are potential concerns given the antigenic variability of the RSV F-protein [40–42], continued vaccine
191 roll-out[4], and recent identification of RSV strains resistant to nirsevimab[43,44].

192 Our assay had similar if not improved precision compared to other assays [29–34]. Our RSV FRNT differs
193 from most other assays with a somewhat lower upper AMR limit of only 4,860 (ND50 or ND80) [45]. Given that
194 only 2.6% ($n=6/226$) of tested clinical specimens exhibit a neutralizing titer (NT) $>10,000$, we found the increased
195 throughput more desirable. We also standardized our RSV FRNT to the First International Standard for Antiserum to
196 Respiratory Syncytial Virus strains A and B, which has been reported for select assays [24]. Our RSV A2 conversion
197 factor of 0.37 is very similar to the 0.38 conversion factor used in a 2021 RSV vaccine clinical trial [46]. In contrast,
198 the RSV A conversion factor from another study was 0.88 [26]. The higher conversion factor is most likely explained
199 by key differences in assay methodology, such as challenge virus, target cell line, and assay readout [24,45]. Our
200 RSV B conversion factor was 0.91, similar to the average conversion factor of 1.1 calculated from NIBSC [27].

201 We found no significant difference in neutralizing titer between individuals serums sampled pre- and post-
202 RSV 2022 outbreak, unlike earlier studies which found evidence of reduced anti-RSV neutralizing titer during the
203 COVID-19 pandemic [11,47]. In agreement with our findings, a 2022 population-immunosurveillance study using
204 methods similar to ours also could not detect waning antibody immune response prior to RSV resurgence [48].
205 Moreover, a recent study attributed approximately two-thirds of the increase in RSV cases to significant increases in
206 volume of RSV testing [49]. Other possible theories behind post-pandemic RSV resurgence, such as SARS-CoV-2-

207 induced immune dysregulation [50–53], changes in population-wide health-seeking behavior [54], and loosening of
208 public health safety measures [8] should also be investigated to inform future vaccination and immunotherapeutic
209 development.

210 Limitations of this study include its cross-sectional design and convenience sampling of remnant clinical
211 specimens for validation. Measurement of pre-and post-outbreak RSV neutralizing titers were limited by the
212 sample size (n=227). Our sample group lacked infants (n=0) and had a limited number of elderly individuals (n=22,
213 12.4%), both of which are especially vulnerable to lowered anti-RSV immunity and severe RSV symptoms[2,57,58].
214 Patients with no reported RSV infection might have experienced unreported RSV infection from the smaller
215 outbreak of winter 2021, potentially inflating neutralizing titers and confounding comparison of pre- and post-2022
216 outbreak populations. RSV strains A2 and B WV/14617/85, classically used for FRNT and PRNT validation[24], were
217 used instead of more contemporary and/or clinical isolates in circulation during the 2022-2023 pandemic[59–61].
218 Differences in sample handling may have influenced measurements. For example, we noticed that GMT across sera
219 of RSV PCR-positive individuals (without immunosuppression) sourced from one hospital trended lower compared
220 to those from the two other hospitals used in the study by 4.43-fold and 2.55-fold respectively, although this
221 difference did not reach statistical significance.

222 Our findings establish the RSV FRNT assay as a high-throughput, accurate neutralization assay sufficiently
223 sensitive to distinguish immunosuppressed and seroconverted individuals from the general population, a
224 diagnostic necessity given the upcoming release of the RSV vaccine. Our immunosurveillance study using this assay
225 found no evidence of immune debt, underlining the uncertainty behind drivers of RSV epidemiology and RSV
226 antibody dynamics, an ever-more concerning gap in knowledge considering the eventuality of the next viral
227 pandemic.

228

229 **Acknowledgments**

230 We thank Dr. Stephanie Goya for insightful discussion and writing assistance. This research received no
231 specific funding and was supported by departmental funds.

232

233 **Conflict of interest**

234 ALG reports contract testing from Abbott, Cepheid, Novavax, Pfizer, Janssen and Hologic and research

235 support from Gilead, outside of the described work.

236

237

238 **Bibliography**

- 239 [1] Respiratory Syncytial Virus (RSV) | NIH: National Institute of Allergy and Infectious
240 Diseases, (2022). [https://www.niaid.nih.gov/diseases-conditions/respiratory-syncytial-](https://www.niaid.nih.gov/diseases-conditions/respiratory-syncytial-virus-rsv)
241 [virus-rsv](https://www.niaid.nih.gov/diseases-conditions/respiratory-syncytial-virus-rsv) (accessed June 10, 2023).
- 242 [2] L.J. Anderson, P.R. Dormitzer, D.J. Nokes, R. Rappuoli, A. Roca, B.S. Graham, Strategic
243 priorities for respiratory syncytial virus (RSV) vaccine development, *Vaccine* 31 (2013)
244 B209–B215. <https://doi.org/10.1016/j.vaccine.2012.11.106>.
- 245 [3] R.D. De Vries, R.L. De Swart, Antibodies face the challenge against human respiratory
246 syncytial virus, *Cell Host Microbe* 31 (2023) 135–136.
247 <https://doi.org/10.1016/j.chom.2022.12.010>.
- 248 [4] O. of the Commissioner, FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine, FDA
249 (2023). [https://www.fda.gov/news-events/press-announcements/fda-approves-first-](https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine)
250 [respiratory-syncytial-virus-rsv-vaccine](https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine) (accessed June 12, 2023).
- 251 [5] G. Pruccoli, E. Castagno, I. Raffaldi, M. Denina, E. Barisone, L. Baroero, F. Timeus, I.
252 Rabbone, A. Monzani, G.M. Terragni, C. Lovera, A. Brach del Prever, P. Manzoni, M.
253 Barbaglia, L. Roasio, S. De Franco, C. Calitri, M. Lupica, E. Felici, C. Marciano, S. Santovito,
254 G. Militerno, E. Abrigo, A. Curtoni, P. Quarello, C. Bondone, S. Garazzino, The Importance of
255 RSV Epidemiological Surveillance: A Multicenter Observational Study of RSV Infection
256 during the COVID-19 Pandemic, *Viruses* 15 (2023) 280.
257 <https://doi.org/10.3390/v15020280>.
- 258 [6] M.-N. Billard, L.J. Bont, Quantifying the RSV immunity debt following COVID-19: a public
259 health matter, *Lancet Infect. Dis.* 23 (2023) 3–5. [https://doi.org/10.1016/S1473-](https://doi.org/10.1016/S1473-3099(22)00544-8)
260 [3099\(22\)00544-8](https://doi.org/10.1016/S1473-3099(22)00544-8).
- 261 [7] I. Garg, R. Shekhar, A.B. Sheikh, S. Pal, Impact of COVID-19 on the Changing Patterns of
262 Respiratory Syncytial Virus Infections, *Infect. Dis. Rep.* 14 (2022) 558–568.
263 <https://doi.org/10.3390/idr14040059>.
- 264 [8] Y.-C. Chuang, K.-P. Lin, L.-A. Wang, T.-K. Yeh, P.-Y. Liu, The Impact of the COVID-19 Pandemic
265 on Respiratory Syncytial Virus Infection: A Narrative Review, *Infect. Drug Resist.* 16 (2023)
266 661–675. <https://doi.org/10.2147/IDR.S396434>.
- 267 [9] P.A. Jorquera, L. Anderson, R.A. Tripp, Understanding respiratory syncytial virus (RSV)
268 vaccine development and aspects of disease pathogenesis, *Expert Rev. Vaccines* 15 (2016)
269 173–187. <https://doi.org/10.1586/14760584.2016.1115353>.
- 270 [10] D. Sun, A. Hsu, J. Quiroz, X. He, M.C. Whiteman, K.B. Gurney, S. Dellatore, Development
271 and comparison of three cell-based potency assays for anti-respiratory syncytial virus
272 monoclonal antibody, *Biologicals* 74 (2021) 1–9.
273 <https://doi.org/10.1016/j.biologicals.2021.10.001>.
- 274 [11] F. Reichertz, R.Y. Xu, B. Abu-Raya, A. Majdoubi, C. Michalski, L. Golding, A. Stojic, M. Vineta,
275 M. Granoski, Z. Cieslak, A. Chacko, N. Desai, I. Sekirov, D.J. Marchant, P.M. Lavoie, Waning
276 Immunity Against Respiratory Syncytial Virus During the Coronavirus Disease 2019
277 Pandemic, *J. Infect. Dis.* 226 (2022) 2064–2068. <https://doi.org/10.1093/infdis/jiac192>.
- 278 [12] S.R. Vaidya, Immuno-Colorimetric Neutralization Test: A Surrogate for Widely Used Plaque
279 Reduction Neutralization Tests in Public Health Virology, *Viruses* 15 (2023) 939.
280 <https://doi.org/10.3390/v15040939>.

- 281 [13] K. S, H. L, S. A.F, P. A, Establishing Correlates of Protection for Vaccine Development:
282 Considerations for the Respiratory Syncytial Virus Vaccine Field, *Viral Immunol.* (2018).
283 <https://doi.org/10.1089/vim.2017.0147>.
- 284 [14] W.P. Glezen, A. Paredes, J.E. Allison, L.H. Taber, A.L. Frank, Risk of respiratory syncytial virus
285 infection for infants from low-income families in relationship to age, sex, ethnic group, and
286 maternal antibody level, *J. Pediatr.* 98 (1981) 708–715. [https://doi.org/10.1016/s0022-](https://doi.org/10.1016/s0022-3476(81)80829-3)
287 [3476\(81\)80829-3](https://doi.org/10.1016/s0022-3476(81)80829-3).
- 288 [15] K.A. Ward, P.R. Lambden, M.M. Ogilvie, P.J. Watt, Antibodies to respiratory syncytial virus
289 polypeptides and their significance in human infection, *J. Gen. Virol.* 64 (Pt 9) (1983) 1867–
290 1876. <https://doi.org/10.1099/0022-1317-64-9-1867>.
- 291 [16] T.M. de Sierra, M.L. Kumar, T.E. Wasser, B.R. Murphy, E.K. Subbarao, Respiratory syncytial
292 virus-specific immunoglobulins in preterm infants, *J. Pediatr.* 122 (1993) 787–791.
293 [https://doi.org/10.1016/s0022-3476\(06\)80027-2](https://doi.org/10.1016/s0022-3476(06)80027-2).
- 294 [17] L.G. Stensballe, H. Ravn, K. Kristensen, K. Agerskov, T. Meakins, P. Aaby, E.A.F. Simões,
295 Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus
296 hospitalization, and recurrent wheeze, *J. Allergy Clin. Immunol.* 123 (2009) 398–403.
297 <https://doi.org/10.1016/j.jaci.2008.10.043>.
- 298 [18] L.G. Stensballe, H. Ravn, K. Kristensen, T. Meakins, P. Aaby, E.A.F. Simoes, Seasonal
299 Variation of Maternally Derived Respiratory Syncytial Virus Antibodies and Association with
300 Infant Hospitalizations for Respiratory Syncytial Virus, *J. Pediatr.* 154 (2009) 296-298.e1.
301 <https://doi.org/10.1016/j.jpeds.2008.07.053>.
- 302 [19] S.R. Vaidya, D.W.G. Brown, L. Jin, D. Samuel, N. Andrews, K.E. Brown, Development of a
303 focus reduction neutralization test (FRNT) for detection of mumps virus neutralizing
304 antibodies, *J. Virol. Methods* 163 (2010) 153–156.
305 <https://doi.org/10.1016/j.jviromet.2009.09.006>.
- 306 [20] Cohen: Plaque reduction neutralization test for measles... - Google Scholar, (n.d.).
307 https://scholar.google.com/scholar_lookup?title=Plaque+reduction+neutralization+test+for+measles+antibodies:+Description+of+a+standardised+laboratory+method+for+use+in+immunogenicity+studies+of+aerosol+vaccination&author=Cohen,+B.J.&author=Audet,+S.&author=Andrews,+N.&author=Beeler,+J.&author=WHO+working+group+on+measles+plaque+reduction+neutralization+test&publication_year=2007&journal=Vaccine&volume=26&pages=59%E2%80%9366&doi=10.1016/j.vaccine.2007.10.046 (accessed September 1,
309 2023).
- 314 [21] S.R. Vaidya, N.S. Kumbhar, V.S. Bhide, Detection of measles, mumps and rubella viruses by
315 immuno-colorimetric assay and its application in focus reduction neutralization tests,
316 *Microbiol. Immunol.* 58 (2014) 666–674. <https://doi.org/10.1111/1348-0421.12201>.
- 317 [22] Z. Wen, M. Citron, A.J. Bett, A.S. Espeseth, K.A. Vora, L. Zhang, D.J. DiStefano, Development
318 and application of a higher throughput RSV plaque assay by immunofluorescent imaging, *J.*
319 *Virol. Methods* 263 (2019) 88–95. <https://doi.org/10.1016/j.jviromet.2018.10.022>.
- 320 [23] Y. Tanino, K. Nishioka, C. Yamamoto, Y. Watanabe, T. Daidoji, M. Kawamoto, S. Uda, S.
321 Kirito, Y. Nakagawa, Y. Kasamatsu, Y. Kawahara, Y. Sakai, S. Nobori, T. Inaba, B. Ota, N.
322 Fujita, A. Hoshino, Y. Nukui, T. Nakaya, Emergence of SARS-CoV-2 with Dual-Drug Resistant
323 Mutations During a Long-Term Infection in a Kidney Transplant Recipient, *Infect. Drug*
324 *Resist.* 17 (2024) 531–541. <https://doi.org/10.2147/IDR.S438915>.

- 325 [24] R. Raghunandan, D. Higgins, N. Hosken, RSV neutralization assays – Use in immune
326 response assessment, *Vaccine* 39 (2021) 4591–4597.
327 <https://doi.org/10.1016/j.vaccine.2021.06.016>.
- 328 [25] G.J. Xu, T. Kula, Q. Xu, M.Z. Li, S.D. Vernon, T. Ndung'u, K. Ruxrungtham, J. Sanchez, C.
329 Brander, R.T. Chung, K.C. O'Connor, B. Walker, H.B. Larman, S.J. Elledge, Comprehensive
330 serological profiling of human populations using a synthetic human virome, *Science* 348
331 (2015) aaa0698. <https://doi.org/10.1126/science.aaa0698>.
- 332 [26] M.C. Crank, T.J. Ruckwardt, M. Chen, K.M. Morabito, E. Phung, P.J. Costner, L.A. Holman,
333 S.P. Hickman, N.M. Berkowitz, I.J. Gordon, G.V. Yamshchikov, M.R. Gaudinski, A. Kumar, L.A.
334 Chang, S.M. Moin, J.P. Hill, A.T. DiPiazza, R.M. Schwartz, L. Kueltzo, J.W. Cooper, P. Chen, J.A.
335 Stein, K. Carlton, J.G. Gall, M.C. Nason, P.D. Kwong, G.L. Chen, J.R. Mascola, J.S. McLellan,
336 J.E. Ledgerwood, B.S. Graham, THE VRC 317 STUDY TEAM, A proof of concept for structure-
337 based vaccine design targeting RSV in humans, *Science* 365 (2019) 505–509.
338 <https://doi.org/10.1126/science.aav9033>.
- 339 [27] J.U. McDonald, P. Rigsby, E. Atkinson, O.G. Engelhardt, Expansion of the 1st WHO
340 international standard for antiserum to respiratory syncytial virus to include neutralisation
341 titres against RSV subtype B: An international collaborative study, *Vaccine* 38 (2020) 800–
342 807. <https://doi.org/10.1016/j.vaccine.2019.10.095>.
- 343 [28] E.M. Burd, Validation of Laboratory-Developed Molecular Assays for Infectious Diseases,
344 *Clin. Microbiol. Rev.* 23 (2010) 550–576. <https://doi.org/10.1128/cmr.00074-09>.
- 345 [29] J. Merluza, J. Ung, K. Makowski, A. Robinson, K. Manguiat, N. Mueller, J. Audet, J.C.-Y.
346 Chen, J.E. Strong, H. Wood, A. Bello, Validation and Establishment of the SARS-CoV-2
347 Lentivirus Surrogate Neutralization Assay as a Prescreening Tool for the Plaque Reduction
348 Neutralization Test, *Microbiol. Spectr.* 11 (2023) e0378922.
349 <https://doi.org/10.1128/spectrum.03789-22>.
- 350 [30] K.S. Omland, A. Brys, D. Lansky, K. Clement, F. Lynn, Participating Laboratories,
351 Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for
352 assessment of functional antibodies in multiple species, *Clin. Vaccine Immunol.* CVI 15
353 (2008) 946–953. <https://doi.org/10.1128/CVI.00003-08>.
- 354 [31] S. Kostense, S. Moore, A. Companjen, A.B.H. Bakker, W.E. Marissen, R. von Eyben, G.J.
355 Weverling, C. Hanlon, J. Goudsmit, Validation of the Rapid Fluorescent Focus Inhibition
356 Test for Rabies Virus-Neutralizing Antibodies in Clinical Samples, *Antimicrob. Agents
357 Chemother.* 56 (2012) 3524–3530. <https://doi.org/10.1128/AAC.06179-11>.
- 358 [32] K. Bohning, S. Sonnberg, H.-L. Chen, M. Zahralban-Steele, T. Powell, G. Hather, H.K. Patel,
359 H.J. Dean, A high throughput reporter virus particle microneutralization assay for
360 quantitation of Zika virus neutralizing antibodies in multiple species, *PLOS ONE* 16 (2021)
361 e0250516. <https://doi.org/10.1371/journal.pone.0250516>.
- 362 [33] S.E. Larsen, B.J. Berube, T. Pecor, E. Cross, B.P. Brown, B.D. Williams, E. Johnson, P. Qu, L.
363 Carter, S. Wrenn, E. Kepl, C. Sydeman, N.P. King, S.L. Baldwin, R.N. Coler, Qualification of
364 ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using
365 human clinical samples, *J. Immunol. Methods* 499 (2021) 113160.
366 <https://doi.org/10.1016/j.jim.2021.113160>.

- 367 [34] E.E. Rhoden, B.A. Mainou, J.L. Konopka-Anstadt, M.S. Oberste, An automated high-
368 throughput enterovirus D68 microneutralization assay platform, *J. Virol. Methods* 308
369 (2022) 114590. <https://doi.org/10.1016/j.jviromet.2022.114590>.
- 370 [35] E. Santana-Rodríguez, M.K. Méndez-Orta, T. Sardina-González, M. Pilar, S.C.- Brizuela, Y.
371 Sordo-Puga, D. Pérez-Pérez, A. Oliva-Cárdenas, M. Vargas-Hernández, C.A. Duarte, M.T.
372 Frías-Lepoureaux, M. Suárez-Pedroso, Consistency of the Neutralizing Peroxidase Linked
373 Assay for Classical Swine Fever and Homologation with an OIE Reference Laboratory,
374 (2022).
- 375 [36] M. Zhu, S. Cloney-Clark, S. Feng, A. Parekh, D. Gorinson, D. Silva, P. Skonieczny, A. Wilson,
376 R. Kalkeri, W. Woo, M.R. Cai, L. Fries, G. Glenn, J.S. Plested, A Severe Acute Respiratory
377 Syndrome Coronavirus 2 Anti-Spike Immunoglobulin G Assay: A Robust Method for
378 Evaluation of Vaccine Immunogenicity Using an Established Correlate of Protection,
379 *Microorganisms* 11 (2023) 1789. <https://doi.org/10.3390/microorganisms11071789>.
- 380 [37] Pan Y.B., Zhang N., Zhan S.S., Gui F., Wang J., Song G., Wu X.L., Yang X.M., Establishment
381 and validation of competitive ELISA for detecting blocking activity of monoclonal antibody
382 against SARS-CoV-2 RBD, *Chin. J. New Drugs* (2020) 2496–2501.
- 383 [38] M.E. Bonhomme, C.J. Bonhomme, L. Strelow, A. Chaudhari, A. Howlett, C. Breidenbach, J.
384 Hester, C. Hammond, M. Fuzy, L. Harvey, V. Swanner, J. Ellis, R.R. Greway, V.A. Pisciella, T.
385 Green, L. Kierstead, Robust validation and performance comparison of immunogenicity
386 assays assessing IgG and neutralizing antibodies to SARS-CoV-2, *PLOS ONE* 17 (2022)
387 e0262922. <https://doi.org/10.1371/journal.pone.0262922>.
- 388 [39] T.M. Timiryasova, P. Luo, L. Zheng, A. Singer, R. Zedar, S. Garg, C. Petit, S. Moore, B.T. Hu, M.
389 Brown, Rapid fluorescent focus inhibition test optimization and validation: Improved
390 detection of neutralizing antibodies to rabies virus, *J. Immunol. Methods* 474 (2019)
391 112626. <https://doi.org/10.1016/j.jim.2019.06.017>.
- 392 [40] A.M. Hause, D.M. Henke, V. Avadhanula, C.A. Shaw, L.I. Tapia, P.A. Piedra, Sequence
393 variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and
394 historical genotypes of RSV/A and RSV/B, *PLoS ONE* 12 (2017) e0175792.
395 <https://doi.org/10.1371/journal.pone.0175792>.
- 396 [41] S. Vandini, C. Biagi, M. Lanari, Respiratory Syncytial Virus: The Influence of Serotype and
397 Genotype Variability on Clinical Course of Infection, *Int. J. Mol. Sci.* 18 (2017) 1717.
398 <https://doi.org/10.3390/ijms18081717>.
- 399 [42] J.A. Melero, M.L. Moore, Influence of Respiratory Syncytial Virus Strain Differences on
400 Pathogenesis and Immunity, in: L.J. Anderson, B.S. Graham (Eds.), *Chall. Oppor. Respir.*
401 *Syncytial Virus Vaccines*, Springer, Berlin, Heidelberg, 2013: pp. 59–82.
402 https://doi.org/10.1007/978-3-642-38919-1_3.
- 403 [43] S.C.J. Jorgensen, Nirsevimab: review of pharmacology, antiviral activity and emerging
404 clinical experience for respiratory syncytial virus infection in infants, *J. Antimicrob.*
405 *Chemother.* 78 (2023) 1143–1149. <https://doi.org/10.1093/jac/dkad076>.
- 406 [44] A.C. Langedijk, E.R. Harding, B. Konya, B. Vrancken, R.J. Lebbink, A. Evers, J. Willemsen, P.
407 Lemey, L.J. Bont, A systematic review on global RSV genetic data: Identification of
408 knowledge gaps, *Rev. Med. Virol.* 32 (2022) e2284. <https://doi.org/10.1002/rmv.2284>.
- 409 [45] N. Hosken, B. Plikaytis, C. Trujillo, K. Mahmood, D. Higgins, A multi-laboratory study of
410 diverse RSV neutralization assays indicates feasibility for harmonization with an

- 411 international standard, *Vaccine* 35 (2017) 3082–3088.
412 <https://doi.org/10.1016/j.vaccine.2017.04.053>.
- 413 [46] E.E. Walsh, A.R. Falsey, D.A. Scott, A. Gurtman, A.M. Zareba, K.U. Jansen, W.C. Gruber, P.R.
414 Dormitzer, K.A. Swanson, D. Radley, E. Gomme, D. Cooper, B. Schmoele-Thoma, for the
415 C3671001 Study Group, A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus
416 Prefusion F Vaccine, *J. Infect. Dis.* 225 (2022) 1357–1366.
417 <https://doi.org/10.1093/infdis/jiab612>.
- 418 [47] G. den Hartog, P.B. van Kasteren, R.M. Schepp, A.C. Teirlinck, F.R.M. van der Klis, R.S. van
419 Binnendijk, Decline of RSV-specific antibodies during the COVID-19 pandemic, *Lancet*
420 *Infect. Dis.* 23 (2023) 23–25. [https://doi.org/10.1016/S1473-3099\(22\)00763-0](https://doi.org/10.1016/S1473-3099(22)00763-0).
- 421 [48] G. Walker, C. Foster, A. Sevdal, A. Domazetovska, A. Kamalakkannan, P.C.M. Williams,
422 K.W. Kim, A. Condylis, S. Stelzer-Braid, A. Bartlett, W. Rawlinson, Genomic and
423 Immunological Characterisation Shows Increased Respiratory Syncytial Virus Cases Not
424 Due to Waning Antibody Mediated Immunity, (2023).
425 <https://doi.org/10.2139/ssrn.4515871>.
- 426 [49] B.A. Petros, C.E. Milliren, P.C. Sabeti, A. Ozonoff, Increased pediatric RSV case counts
427 following the emergence of SARS-CoV-2 are attributable to increased testing, (2024)
428 2024.02.06.24302387. <https://doi.org/10.1101/2024.02.06.24302387>.
- 429 [50] B. Kratzer, D. Trapin, P. Ettel, U. Körmöczy, A. Rottal, F. Tuppy, M. Feichter, P. Gattinger, K.
430 Borochova, Y. Dorofeeva, I. Tulaeva, M. Weber, K. Grabmeier-Pfistershammer, P.A. Tauber,
431 M. Gerdov, B. Mühl, T. Perkmann, I. Fae, S. Wenda, H. Führer, R. Henning, R. Valenta, W.F.
432 Pickl, Immunological imprint of COVID-19 on human peripheral blood leukocyte
433 populations, *Allergy* 76 (2021) 751–765. <https://doi.org/10.1111/all.14647>.
- 434 [51] Y. Jing, L. Luo, Y. Chen, L.S. Westerberg, P. Zhou, Z. Xu, A.A. Herrada, C.-S. Park, M. Kubo, H.
435 Mei, Y. Hu, P.P.-W. Lee, B. Zheng, Z. Sui, W. Xiao, Q. Gong, Z. Lu, C. Liu, SARS-CoV-2 infection
436 causes immunodeficiency in recovered patients by downregulating CD19 expression in B
437 cells via enhancing B-cell metabolism, *Signal Transduct. Target. Ther.* 6 (2021) 1–13.
438 <https://doi.org/10.1038/s41392-021-00749-3>.
- 439 [52] J. Liu, X. Yang, H. Wang, Z. Li, H. Deng, J. Liu, S. Xiong, J. He, X. Feng, C. Guo, W. Wang, G.
440 Zelinsky, M. Trilling, K. Sutter, T. Senff, C. Menne, J. Timm, Y. Zhang, F. Deng, Y. Lu, J. Wu,
441 M. Lu, D. Yang, U. Dittmer, B. Wang, X. Zheng, Analysis of the Long-Term Impact on Cellular
442 Immunity in COVID-19-Recovered Individuals Reveals a Profound NKT Cell Impairment,
443 *mBio* 12 (2021) 10.1128/mbio.00085-21. <https://doi.org/10.1128/mbio.00085-21>.
- 444 [53] C. Phetsouphanh, D.R. Darley, D.B. Wilson, A. Howe, C.M.L. Munier, S.K. Patel, J.A. Juno,
445 L.M. Burrell, S.J. Kent, G.J. Dore, A.D. Kelleher, G.V. Matthews, Immunological dysfunction
446 persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection, *Nat.*
447 *Immunol.* 23 (2022) 210–216. <https://doi.org/10.1038/s41590-021-01113-x>.
- 448 [54] B. Abu-Raya, M.V. Paramo, F. Reicherz, P.M. Lavoie, Why has the epidemiology of RSV
449 changed during the COVID-19 pandemic?, *eClinicalMedicine* 61 (2023).
450 <https://doi.org/10.1016/j.eclinm.2023.102089>.
- 451 [55] C. j. Sande, M. n. Mutunga, E. a. Okiro, G. f. Medley, P. a. Cane, D. j. Nokes, Kinetics of the
452 Neutralizing Antibody Response to Respiratory Syncytial Virus Infections in a Birth Cohort,
453 *J. Med. Virol.* 85 (2013) 2020–2025. <https://doi.org/10.1002/jmv.23696>.

- 454 [56] B.N. Blunck, L. Aideyan, X. Ye, V. Avadhanula, L. Ferlic-Stark, L. Zechiedrich, B.E. Gilbert, P.A.
455 Piedra, A prospective surveillance study on the kinetics of the humoral immune response
456 to the respiratory syncytial virus fusion protein in adults in Houston, Texas, *Vaccine* 39
457 (2021) 1248–1256. <https://doi.org/10.1016/j.vaccine.2021.01.045>.
- 458 [57] R.T. Stein, H.J. Zar, RSV through the COVID-19 pandemic: Burden, shifting epidemiology,
459 and implications for the future, *Pediatr. Pulmonol.* 58 (2023) 1631–1639.
460 <https://doi.org/10.1002/ppul.26370>.
- 461 [58] L.M. Stephens, S.M. Varga, Considerations for a Respiratory Syncytial Virus Vaccine
462 Targeting an Elderly Population, *Vaccines* 9 (2021) 624.
463 <https://doi.org/10.3390/vaccines9060624>.
- 464 [59] M. Redlberger-Fritz, D.N. Springer, S.W. Aberle, J.V. Camp, J.H. Aberle, Respiratory syncytial
465 virus surge in 2022 caused by lineages already present before the COVID-19 pandemic, *J.*
466 *Med. Virol.* 95 (2023) e28830. <https://doi.org/10.1002/jmv.28830>.
- 467 [60] S. Goya, J. Sereewit, D. Pfalmer, T.V. Nguyen, S.A.K.M. Bakhsh, E.B. Sobolik, A.L. Greninger,
468 Genomic Characterization of Respiratory Syncytial Virus during 2022-23 Outbreak,
469 Washington, USA, *Emerg. Infect. Dis.* 29 (2023) 865–868.
470 <https://doi.org/10.3201/eid2904.221834>.
- 471 [61] G. Adams, G.K. Moreno, B.A. Petros, R. Uddin, Z. Levine, B. Kotzen, K. Messer, S.T. Dobbins,
472 K.C. DeRuff, C. Loreth, T. Brock-Fisher, S.F. Schaffner, S. Chaluvadi, S. Kanjilal, J. Luban, A.
473 Ozonoff, D. Park, S. Turbett, K.J. Siddle, B.L. MacInnis, P. Sabeti, J.E. Lemieux, RSV Surge in
474 the USA and Viral Lineages, 2022, *N. Engl. J. Med.* 388 (2023) 1335–1337.
475 <https://doi.org/10.1056/NEJMc2216153>.
- 476 [62] RSV State Trends - NREVSS | CDC, (2024).
477 <https://www.cdc.gov/surveillance/nrevss/rsv/state.html> (accessed February 27, 2024).
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497

498 **Table 1: ND50 values, expressed in IU/mL, obtained by the RSV FRNT assay using RSV A2 as the challenge virus**
499 **are within 2-fold of independent published estimates.**

sample	n	ND50 RSV FRNT (IU/mL) ^{a,c}	ND50 reference (IU/mL) ^{b,c}	ratio of ND50 RSV FRNT / reference
NR-21973	5	9,539	6,830	1.4
NR-4020	5	1,392	1,236	1.1
NR-4021	6	4,154	4,404	0.9
NR-4022	6	898	706	1.3
NR-4023	12	1,114	625	1.8

500 ^aNIBSC 16/284 standard was tested twelve times with RSV A2, with geometric mean 5404.8. To convert ND50
501 values to IU/mL, ND50 values obtained in the RSV FRNT assay are multiplied by 0.37.

502 ^bReference values were taken from an independent publication, which used an IU/mL conversion factor of
503 0.88[26].

504 ^cData represents the geometric mean.

505

506

507 **Table 2: ND50 values, expressed in IU/mL, obtained by the RSV FRNT assay using RSV B WV/14617/85 as**
508 **challenge virus are within 2-fold of independent published estimates.**

sample	n	ND50 RSV FRNT (IU/mL) ^{a,c}	ND50 reference (IU/mL) ^{b,c}	ratio of ND50 RSV FRNT / reference
NR-21973	6	1,107	1,005	1.1
NR-4022	6	13,738	12,059	1.1

509 ^aNIBSC 16/284 standard was tested 6 times, with geometric mean 2,195.8. To convert ND50 values to IU/mL,
510 ND50 values obtained in the RSV FRNT assay are multiplied by 0.91. In the reference article, mean conversion
511 factor across all assays reported was 1.1; the reference did not report conversion factor per-assay[27].

512 ^bReference values obtained from independent publication (no conversion factor provided)[27].

513 ^cData represents the geometric mean.

514

515

516 **Figure Legends**

517 **Figure 1. The RSV FRNT assay results are strongly correlated with ELISA measurements and meet our linearity**
518 **and precision requirements.** A) Shown are the results of RSV-binding antibody measurement by ELISA of the
519 linearity panel specimens (black open circles; see Assay Accuracy), rubella serology remnant specimens (blue open
520 circles), and the Ig-depleted negative control (red closed circle, NR-49447). Dashed black line is the 4-parameter
521 logistic curve fit of the ELISA results from the linearity panel only ($R^2 = 0.96$). Sera was measured in duplicate,
522 normalized relative to the assay cutoff control (relative absorbance of ten), and plotted as average values. The
523 standard deviation of the measurements is plotted as a black line range. In most cases, the standard deviation was
524 smaller than the diameter of the plotted points obscuring the standard deviation line range. Values with relative
525 absorbance less than nine are considered negative since they fall below the cutoff. Values with relative absorbance
526 between 9 and 11 are inconclusive. Values with relative absorbance greater than 11 are positive for RSV-reactive
527 antibodies. B) RSV FRNT ND50 and ND80 values from testing of the linearity panel. The range of mean ND50 results
528 include from 15.1 to 16,093.2 and the range of mean ND80 results include from 14.9 to 5308.7. The dashed lines
529 (black for ND50 and blue for ND80) are the best fit from the linear regression analysis. C) Linearity panel specimens
530 (the same used in panel A and B) ranging in expected ND50 values from 55 to 14,982, were measured in duplicate
531 over 3 days. Every sample exhibited GCV < 37%, meeting our acceptance criteria for precision. Green boxes
532 demarcate boundaries of expected variation for a GCV of 37%. Solid lines represent mean ND50 for panel member.
533 D) Five serum specimens from rubella remnant testing with known ND50s/ND80s spanning the AMR of the assay
534 were selected and tested in duplicate over two days. Every sample exhibited GCV < 37%, meeting our acceptance
535 criteria for precision. Green boxes demarcate boundaries of expected variation for a GCV of 37%. Solid lines
536 represent mean ND50 for panel member.

537

538 **Figure 2. Distribution of neutralizing titers among random population samples collected from late 2021 to early**
539 **2024.** A) The ND50 neutralizing titer results of HSV serology remnant serum specimens from individuals sampled
540 around February 2022, August 2022, February 2023, and September 2023, with date of serum collection on x-axis.
541 For each cross-sectional group, dashed and solid lines represent geometric median and geometric mean,
542 respectively. B) Number of positive RSV antigen tests across time. Data obtained from CDC Washington State

543 trends[62], reported as 5 week average. Log₂-transformed data was analyzed, using a two-sided student's T-test to
544 compare groups pairwise.

545

546 **Figure 3. Distribution of neutralizing titers among RSV negative, positive, and future-infected individuals relative**
547 **to a random population sample.** ND50 neutralizing titer for individuals sampled from October 2021 to February
548 2024. Solid lines represent geometric mean. HSV serology remnant specimens: a random population sample of
549 remnant sera sent for clinical HSV remnant testing, collected from February 2021 to September 2023, with
550 unknown testing status for RSV. Future RSV-infected: HSV remnant samples (not part of the HSV serology remnant
551 specimen group above) from individuals who tested positive for RSV 25 or more days after serum collection date.
552 RSV PCR+, immunocompetent: emergency department (ED) patients PCR-positive for RSV 98 days before to 7 days
553 after serum collection. RSV PCR+, immunosuppressed: ED patients PCR-positive for RSV 49 days before to 7 days
554 after serum collection, with medical status of immunosuppression at time of test/collection. Influenza+, RSV-: ED
555 patients with no recorded RSV-positive or immunosuppression status who tested PCR-positive for influenza 39 days
556 before to 7 days after serum collection. Log₂-transformed data was analyzed, using a two-sided student's T-test to
557 compare groups pairwise.

558





